Icon of the Instituts for Quality and Efficiency in Health Care

Dossier assessment

Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A20-28
Last updated

Report documents

  1. Extract of dossier assessment

    Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 406 kB, EN, not accessible
    Download file : Extract of dossier assessment (PDF document, 406 kB, EN, not accessible)

  2. Dossier assessment

    Ceftolozane/tazobactam (complicated urinary tract infections) - Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 682 kB, DE, not accessible
    Download file : Dossier assessment (PDF document, 682 kB, DE, not accessible)

Press releases

Ceftolozane/tazobactam: new treatment option for severe infections, but no proof of superiority

Informative comparative data are missing / resistance situation not sufficiently considered in approval studies
Press release

Project details

Project no.
A20-28
Commission
Commission awarded on 17.03.2020 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Immune system and infections
Note

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Connected Projects

  1. Dossier assessment

    Ceftolozane/tazobactam (complicated intra-abdominal infections) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-27
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Ceftolozane/tazobactam (hospital-acquired pneumonia) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-26
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Ceftolozane/tazobactam (acute pyelonephritis) - Benefit assessment according to §35a Social Code Book V

    Project no.
    A20-29
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Ceftolozane/tazobactam (bacterial infections) - Assessment according to §35a (para. 1c) Social Code Book V

    Project no.
    G22-18
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Ceftolozane/tazobactam (bacterial infections < 18 years) - Assessment according to §35a (para. 1c) Social Code Book V

    Project no.
    G22-27
    Last updated

    Status: Commission completed

Contact

Press contact

+49 221 356850

press@iqwig.de

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form

Print page